Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

被引：0
|
作者：
Satoshi Watanabe
Junta Tanaka
Takeshi Ota
Rie Kondo
Hiroshi Tanaka
Hiroshi Kagamu
Kosuke Ichikawa
Jun Koshio
Junko Baba
Takao Miyabayashi
Ichiei Narita
Hirohisa Yoshizawa
机构：
[1] Niigata University Medical and Dental Hospital,Department of Medicine (II)
[2] Niigata University Medical and Dental Hospital,Bioscience Medical Research Center
来源：
BMC Cancer | / 11卷
关键词：
Overall Survival; Gefitinib; Erlotinib; NSCLC Patient; Disease Control Rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Okamoto, Norio
    Yamadori, Tadahiro
    Tamiya, Motohiro
    Morishita, Naoko
    Shiroyama, Takayuki
    Otsuka, Tomoyuki
    Kitai, Kanako
    Kawase, Ichiro
    CHINESE JOURNAL OF CANCER, 2013, 32 (03) : 136 - 140
  • [42] CLINICAL MODES OF EGFR TYROSINE KINASE INHIBITOR FAILURE AND SUBSEQUENT MANAGEMENT IN ADVANCED NON-SMALL CELL LUNG CANCER
    Chen, H.
    Yang, J.
    Yan, H.
    Zhang, X.
    Wu, Z.
    Wu, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 437 - 437
  • [43] Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer
    Yang, Jin-Ji
    Chen, Hua-Jun
    Yan, Hong-Hong
    Zhang, Xu-Chao
    Zhou, Qing
    Su, Jian
    Wang, Zhen
    Xu, Chong-Rui
    Huang, Yi-Sheng
    Wang, Bin-Chao
    Yang, Xue-Ning
    Zhong, Wen-Zhao
    Nie, Qiang
    Liao, Ri-Qiang
    Jiang, Ben-Yuan
    Dong, Song
    Wu, Yi-Long
    LUNG CANCER, 2013, 79 (01) : 33 - 39
  • [44] Clinical experience on EGFR tyrosine kinase inhibitor in non-small cell lung cancer, compassionate programme in Czech Republic
    Pesek, M.
    Skrickova, J.
    Kolek, V.
    Zatloukal, P.
    Petruzelka, L.
    Svobodnik, A.
    LUNG CANCER, 2006, 52 : S27 - S27
  • [45] Predictive efficacy of 11C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients
    Dai, Dong
    Li, Xiao-Feng
    Wang, Jian
    Liu, Jian-Jing
    Zhu, Yan-Jia
    Zhang, Ying
    Wang, Qi
    Xu, Wen-Gui
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (04) : 1003 - 1012
  • [46] Survivin mRNA expression in blood as a predictor of the response to EGFR-tyrosine kinase inhibitors and prognosis in patients with non-small cell lung cancer
    Wei-Lin Shi
    Jian Li
    Quan-Lei Bao
    Jian-Nong Wu
    Li-Ping Ge
    Li-Rong Zhu
    Yi Wang
    Wen-Fang Zhu
    Medical Oncology, 2014, 31
  • [47] Cetuximab combined with chemotherapy is beneficial for patients with advanced non-small cell lung cancer after EGFR-tyrosine kinase inhibitors failure
    Zhang, Feng
    Yu, You
    Xing, Lina
    Chen, Min
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (09): : 16140 - 16148
  • [48] RETROSPECTIVE ANALYSIS FOR CLINICAL CHARACTERISTICS OF ACQUIRED RESISTANCE TO GEFITINIB IN NON-SMALL CELL LUNG CANCER PATIENTS
    Kim, Hye Ryun
    Kim, Young Chul
    Kim, Kyu Sik
    Ban, Hee Jung
    Lee, Sung Yong
    Jang, Tae Won
    Shin, Kyeong Cheol
    Lee, Gwan Ho
    Ryu, Jeong Seon
    Jang, Seung Hoon
    Lee, Jeong Eun
    Kim, Sun Young
    Kim, Hee Joung
    Young, Kye
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S665 - S665
  • [49] CLINICAL EXPERIENCE USE GEFITINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH A MUTATION EGFR
    Vozniy, Eduard
    Popov, Anatoly
    Galkin, Michail
    Astrakhankina, Tamara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1214 - S1214
  • [50] Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India
    Garg, Avneet
    Batra, Ullas
    Choudhary, Priyanshu
    Jain, Deepali
    Khurana, Sachin
    Malik, Prabhat S.
    Muthu, Valliappan
    Prasad, K. T.
    Singh, Navneet
    Suri, Tejas
    Mohan, Anant
    CURRENT PROBLEMS IN CANCER, 2020, 44 (03)
12345